603811 Zhejiang Cheng Yi Pharmaceutical
- 6.62
- -0.01-0.15%
Zhejiang Cheng Yi Pharmaceutical News
Zhejiang Cheng Yi Pharmaceutical (603811.SH) annual equity distribution in 2023: distribute 0.2 yuan per share, with June 7 as the record date.
Zhejiang Cheng Yi Pharmaceutical (603811.SH) released the implementation announcement of 2023 annual equity distribution, and the profit distribution this time is based on ...
Chengyi Pharmaceutical (603811.SH): Net profit of 32.685 million yuan in the first quarter, down 17.77% year on year
On April 25, Ge Longhui Pharmaceutical (603811.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 153 million yuan, an increase of 3.54%; net profit attributable to shareholders of listed companies was 32.685 million yuan, a year-on-year decrease of 17.77%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 308.902 million yuan, a year-on-year decrease of 20.40%; and basic earnings per share were 0.1 yuan.
Express News | Sincerity Pharmaceutical: Lidocaine hydrochloride injection passed generic drug consistency evaluation
Sincerity Pharmaceutical (603811.SH): The controlling shareholders' concerted actions increased their total shareholding by 1.05%
On March 7, Gelonghui Pharmaceutical (603811.SH) announced that as of the disclosure date of this announcement, the controlling shareholders' concerted actions increased their holdings by a total of 3,424,722 shares, accounting for 1.05% of the company's total share capital.
Express News | Nearly 20 listed companies disclosed plans to repurchase or increase holdings after the market and announced that Zhifei Biotech plans to buy back 300 million yuan and use it for cancellation
Express News | Sincerity Pharmaceutical: The controlling shareholder plans to increase the company's shares by 15 million yuan to 30 million yuan
Chengyi Pharmaceutical (603811.SH): Shareholder Yan Xiaoling increased her shareholding by a total of 2.266 million yuan
Gelonghui, Feb. 21丨Chenyi Pharmaceutical (603811.SH) announced that as of the disclosure date of this announcement, the company had received Ms. Yan Xiaoling's “Notice Letter on the Completion of the Implementation Plan”. Ms. Yan Xiaoling had reached the minimum implementation amount of the plan to increase her holdings and had completed the plan to increase her holdings. Ms. Yan Xiaoling increased her holdings of the company's shares by a total of 349,722 shares, accounting for 0.11% of the company's total share capital. The cumulative increase amount of her holdings was 2.266,600 yuan (excluding taxes and fees), exceeding her plan to increase her holdings by no less than RMB 1.5 million and no more than RMB 3 million, and completed the agreement to increase her holdings.
Cheng Yi Pharmaceutical Shareholder Boosts Stake in Firm
A controlling shareholder of Zhejiang Cheng Yi Pharmaceutical (SHA:603811) bought more shares in the company. Yan Xiaoling acquired an additional 213,022 shares in the Chinese pharmaceutical firm, acc
Sincerity Pharmaceutical (603811.SH): Controlling shareholder Yan Xiaoling increased her holdings by a total of 21.3 million shares
Gelonghui, Feb. 6, 丨 Chenyi Pharmaceutical (603811.SH) announced that on February 6, 2024, the company learned that based on confidence in the company's future development and recognition of long-term investment value, in order to promote the company's sustainable, stable and healthy development, Ms. Yan Xiaoling, the controlling shareholder of the company, increased her holdings of the company's shares by a total of 213,022 million shares, accounting for 0.065% of the company's total shares.
Benign Growth For Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHSE:603811) Underpins Stock's 28% Plummet
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHSE:603811) shareholders that were waiting for something to happen have been dealt a blow with a 28% share price drop in the last month. Instead of bein
Sincerity Pharmaceutical (603811.SH): EPA raw materials are still in the process of being declared and are communicating with interested customers
Gelonghui, January 25 | Chenyi Pharmaceutical (603811.SH) said on the investor interactive platform that our EPA ingredients are still in the process of being declared, are in communication with intended customers, and have not yet received overseas orders. Our high-purity fish oil and ceric acid series foods are currently sold at the “Sankang Nutrition and Health Official Flagship Store” in the Jingdong Mall, and promotions will also be carried out from time to time.
Chengyi Pharmaceutical (603811.SH): The holding subsidiary passed the high-tech enterprise certification
Gelonghui, January 24, 丨 Chenghui Pharmaceutical (603811.SH) announced. Recently, the Office of the National High-tech Enterprise Certification and Management Leading Group issued the “Notice on Filing the Second Batch of High-tech Enterprises Certified by Fujian Accreditation Agencies in 2023". The company's holding subsidiary Fujian Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as “Huakang Pharmaceutical”) was included in the second batch of high-tech enterprise filing list certified and reported by the Fujian Provincial Accreditation Agency in 2023. Certificate number: GR202335003219, date of issue: December 28, 2023 Validity period: 3 years. This week
Sincerity Pharmaceutical (603811.SH): Recertified as a high-tech enterprise
Gelonghui, December 29, 丨 Chenghui Pharmaceutical (603811.SH) announced. Recently, the Office of the National High-tech Enterprise Certification and Management Leading Group issued the “Notice on Filing High-tech Enterprises with 2023 Certification Report by Zhejiang Accreditation Agency”. The company was included in the Zhejiang Accreditation Agency's 2023 high-tech enterprise filing list, certificate number: GR202333006749, date of issue: December 8, 2023, validity period: three years. The company's current certification of a high-tech enterprise is a re-certification after the original certificate expires.
Sincerity Pharmaceutical (603811.SH): Douyin has not yet invested in a large number of operations due to the platform, and is currently operated independently by our company
On December 5, Gelonghui Pharmaceutical (603811.SH) stated on the investor interactive platform that currently the JD store is maintained by a dedicated operator, and the customer service is handled by our employees. Since we are currently in the e-commerce festival period, there are multiple sets of promotions for the same product. The details are subject to the image display. If you have any questions, please contact our back office customer service. In the future, we will strengthen the training of customer service personnel and use professional customer service personnel. Douyin has not yet invested in a large number of operations due to the platform; currently, it is operated independently by our company.
Sincerity Pharmaceutical (603811.SH): As the population ages and living standards improve, the demand for ammonia sugar will increase further
On November 16, Gelonghui Pharmaceutical (603811.SH) said at the performance briefing that as the population ages and living standards improve, the demand for ammonia sugar will increase further.
Chengyi Pharmaceutical (603811.SH): Focusing on planning Asia's largest annual production of 2,000 tons of ammonia sugar APIs and 1,000 tons of pharmaceutical-grade high-purity EPA “two strengths and one big” project
Gelonghui November 16丨Chengyi Pharmaceutical (603811.SH) said at the performance briefing that during the “14th Five-Year Plan” period, Chenyi Pharmaceutical will closely focus on the three development directions of “marine medicine, biomedicine, and traditional Chinese medicine” and the “10 billion market value, century-old enterprise” goal of “10 billion market capitalization, century-old enterprise”, focusing on the “two strengths and one big” project, focusing on the big health industry and striving to achieve the whole process, full product category and chain layout of the entire chain, from food to health products Strive to seize the strategic high ground and empower the enterprise with new value, Realize corporate groupings and high quality
Chengyi Pharmaceutical (603811.SH): Ammonose capsules have been purchased by the country for three years. They expire at the end of October this year, and renewal is currently in progress
On November 16, Gelonghui Pharmaceutical (603811.SH) said at the performance briefing that the national procurement of ammonia sugar capsules is three years old and expires at the end of October this year. Currently, renewals are in progress. Some provincial policies have not yet been issued. The official documents of the 14 provinces led by Henan have not yet been issued and are awaiting. According to the overall arrangement, the one-enterprise, one-province policy that will cancel national procurement, many companies will participate in the quotation and selection of one province. The volume will increase in the future, and prices will be lowered.
Sincerity Pharmaceutical (603811.SH): Currently, EPA generic drugs are in the acceptance stage, and the normal approval time is expected to be about one year
On November 16, Gelonghui Pharmaceutical (603811.SH) stated at the performance briefing that EPA generic drugs are currently in the acceptance stage, and it is expected that the normal approval time will be about one year. Currently, fish oil softgels from companies such as Shengdi Pharmaceutical and Colon Pharmaceutical have already been declared. Compared with competing products, Chengyi Pharmaceutical has the advantage of integrating API formulations in the EPA field. In terms of overall industry layout, we strive to become the manufacturer with the largest domestic production capacity and the most complete industrial chain.
Sincerity Pharmaceutical (603811.SH): The US API DMF filing schedule is around the first half of next year
On November 16, Gelonghui Pharmaceutical (603811.SH) stated at the performance briefing that the company's EPA API uses both the Chinese and US declarations, and the US API DMF filing schedule is around the first half of next year. We are already in touch with our potential customers, and there are plans to expand the international market for fish oil pharmaceutical products.
Sincerity Pharmaceutical (603811.SH): Complete the filing of domestic health food
On November 14, Gelonghui Pharmaceutical (603811.SH) announced that the company's “Guanchengbao Fish Oil Softgels” and “Yikanggu Fish Oil Softgels” products have completed the domestic health food filing process and obtained domestic health food filing certificates issued by the State Administration of Market Supervision and Administration.
Analysis
Price Target
No Data
